Assessing Immunotherapy Toxicity in NHPs

Engineered T cells expressing high-affinity chimeric antigen receptors (CARs) confer remarkable tumor specificity by recognizing patient-specific tumor antigens and triggering antitumor activities.

COVID-19 represents a global crisis, yet significant knowledge gaps remain about human immunity to SARS-CoV-2. As many researchers raced to develop the vaccines and therapeutics needed to mitigate the pandemic, other investigators took up the task of understanding the human body’s diverse response to this virus. With technology advancing exponentially, researchers have an arsenal of analytic tools now at their disposal to decipher the most elusive aspects of viral immunobiology.

Understanding cell-to-cell interactions in a tumor microenvironment are increasingly challenging due to the complexity of cancer cells. Existing cell culture methods to visualize cancer cell interactions are limited to mono-layer culture with few established co-culture techniques.

Privately held Aprecia Pharmaceuticals, LLC (Aprecia) and CMIC CMO Co., LTD (CMIC CMO) today announced that both companies will collaborate to develop business opportunities in Japan for Aprecias ZipDoseTechnology. CMIC CMOs services will include identifying prospects in Japan, generating awareness and facilitating discussions of technology licensing agreements, research collaborations and distribution partnerships. Through this engagement Aprecia seeks to expand its 3DP products globally, and this agreement highlights the importance of Japan in its long term strategy.